Dechert advised Antios Therapeutics on the deal.Antios Therapeutics, Inc. (“Antios”) completed its $96 million Series B financing. Antios is a clinical-stage biopharmaceutical company focused on the development…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
